Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Key facts

Sponsor

Canadian Cancer Trials Group

Principal Investigator

David Cescon

University Health Network, Princess Margaret Hospital, Toronto ON Canada

Intervention

RP-6306(drug)

Eligibility

All sexes

Timeline

2023 – 2027

Study locations (10)

• Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
• BCCA - Kelowna, Kelowna, British Columbia, Canada
• BCCA - Vancouver, Vancouver, British Columbia, Canada
• QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
• Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
• Kingston Health Sciences Centre, Kingston, Ontario, Canada
• Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
• Odette Cancer Centre, Toronto, Ontario, Canada
• University Health Network, Toronto, Ontario, Canada
• The Jewish General Hospital, Montreal, Quebec, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare malignant breast tumor

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNANCT06255808
  Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
  Seoul National University Hospital
• RECRUITINGNANCT06523452
  Laser Speckle Imaging During Breast Reconstruction
  Royal Devon and Exeter NHS Foundation Trust
• RECRUITINGPHASE1NCT06239467
  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
  OnKure, Inc.
• ACTIVE NOT RECRUITINGPHASE1NCT06206837
  A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
  Pfizer
• ACTIVE NOT RECRUITINGNANCT06234488
  Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
  Medical College of Wisconsin
• ENROLLING BY INVITATIONNANCT07206888
  Advanced Ultrasound Signal Processing of Suspicious Breast Images
  Johns Hopkins University
• ACTIVE NOT RECRUITINGPHASE3NCT01674140
  S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
  SWOG Cancer Research Network
• ACTIVE NOT RECRUITINGPHASE3NCT01349322
  Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
  Radiation Therapy Oncology Group

See all trials for Rare malignant breast tumor →